Clinical Trial Update: Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating Ologen (OculusGen) for glaucoma and pterygium using a historical control, completed at Beijing Remin Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Pterygium

Drugs mentioned

• Ologen

Snippet

Sponsor: Pro Top & Mediking Company Limited | Conditions: Glaucoma, Pterygium | Phase 3 | Status: COMPLETED